In 2008, the FDA approved the use of a neuromodulation technique called repetitive transcranial magnetic stimulation, or rTMS, for the treatment of Treatment Resistant Depression (TRD). Since that time, the evidence continues to mount supporting the use of rTMS to help patients whose depression does not respond to traditional treatments. In order to realize the full potential of rTMS, more large-scale clinical research is needed to establish its effectiveness, encouraging more widespread utilization and insurance reimbursement.
As a vital first step, the rTMS Task Group has developed the first data registry to standardize research and clinical data on rTMS from NNDC Centers utilizing the technique. The team has also designed a treatment protocol to help clinicians determine the most effective dosing for rTMS.
Task group member Dr. Oscar Morales discusses the benefits of rTMS for treatment resistant depression while treating patients at member site Mclean Hospital